Date

Tuesday, June 28, 2022

Venue

Time

09:00 (GMT+7)

Agenda

AGMS

1. Approval of the company's annual report of the financial year 2021, reviewed by Board of commissioners, including the ratification of the consolidated financial statements of the company and subsidiaries of the financial year 2021, audited by the public accounting firm Tanudiredja, Wibisana, Rintis & Rekan (member of firm global network PwC) and signed on May 27, 2022; and to release and discharge of all responsibilities (volledig acquit et de charge) to all Board members for the management and supervision carried out, and  reflected in the company's annual report and the consolidated financial statements of the company and subsidiaries of the financial year 2021.
2. Approval on the determination of salaries and allowances for Board of Directors, and the determination of the honorarium and/or allowances for Board of Commissioners of the financial year 2022
3. Approval to elect an Independent Public Accountant to audit the company's consolidated financial statements of the financial year 2022 and to determine the honorarium of the Public Accountant.
4. Proceeds usage report from the Initial Public Offering.
5. Approval on the renewal of the delegation of authority to Board of Commissioners for the new shares issuance in connection with the International Initial Public Offering.
6. Approval on the renewal of the transfer of authority to Board of Commissioners for the new shares issuance to be granted to Board members, and/or employees of the company and subsidiaries based on the Share Ownership Program.
7. Approval of the change of the company's status from a foreign investment company to a domestic investment company.
8. Approval of the capital increase without pre-emptive rights of up to 10% of the issued and paid-up capital of the company.
9. Approval of changes to the Board members composition.
10. Approval of amendments to the company's Articles of Association in connection with (i) changes in the company's Status; and (ii) an increase in the issued and paid-up capital as the implementation of the capital increase without pre-emptive right up to a maximum of 10% of the issued and paid-up capital of the company.